Navigation Links
Clinical Study Shows Regenecare Relieves Pain and Itching of Skin,Rashes Caused by Widely Used Cancer Drugs

IRVING, Texas--(BUSINESS WIRE)--Jul 11, 2007 - The Journal of the American Society of Clinical Oncology has published the early results of a clinical study conducted by Dr. Siu-Fun Wong, and her colleagues, which concluded that the topical gel, Regenecare(R), caused a statistically significant reduction in the pain and itching of a rash that results from the use of anti-cancer drugs known as EGFR inhibitors. This ongoing supportive care trial is listed on the National Cancer Institute Clinical Trials website (www.cancer.gov).

Paul Miller, President of MPM Medical, stated, "EGFR inhibitors form a group of drugs, sold by several pharmaceutical companies, which are effective in the treatment of cancer. However, after a few weeks of use, an acne-like rash often appears on the face, neck, back, hands, and/or legs resulting in severe pain and itching for the patient. We know of no other evidence-based topical applications reported in the scientific literature shown to help manage rash symptoms caused by EGFR drugs."

Regenecare(R) is a proprietary product of MPM Medical, Inc., a wholly owned subsidiary of RBC Life Sciences, Inc. (OTCBB:RBCL).

MPM Medical develops and markets a line of prescription and nonprescription products for wound management, through medical-surgical dealers, to nursing homes, hospitals, and cancer clinics.

The statements above, other than statements of historical facts, may be forward-looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.

Contact

RBC Life Sciences, Inc.
Steve Brown, CFO, 972-893 4000





Page: 1 2

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
3. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... N.C., Jan. 19, 2011 As Pisgah Laboratories, Inc. ... it will soon begin scale-up of its patent-pending form ... of hydrocodone which imparts abuse deterrent properties to a ... clinical trials in their FDA / DEA registered facility. ...
... Medical Group Inc. (Nasdaq: WWIN ), ("Winner ... medical disposables and non-woven fabric made from 100% natural ... will participate in Arab Health 2011, to be held ... Exhibition Centre in Dubai, UAE. During ...
Cached Medicine Technology:Abuse Deterrent Hydrocodone / Acetaminophen Leads NDA Pipeline 2Abuse Deterrent Hydrocodone / Acetaminophen Leads NDA Pipeline 3Winner Medical to Participate in Arab Health 2011, International Healthcare Exhibition, in Dubai 2Winner Medical to Participate in Arab Health 2011, International Healthcare Exhibition, in Dubai 3
(Date:7/11/2014)... H.E.A.R Me Out Listens to Needs of ... to provide comprehensive information and services available to Colorado’s ... Coloradoans with hearing loss, this organization is the first ... the local and state resources that aims to give ... H.E.A.R. Me Out and its website was founded by ...
(Date:7/11/2014)... Having experienced mental illness from the perspectives ... hospital staff, Roger Grainger gives readers an intimate look at ... book, “You Never Get Out.” , According to the Mental ... will experience some kind of mental health problem in the ... take a look at the way mental illness is addressed ...
(Date:7/11/2014)... of personalized medicine may be just around the corner, ... Min Yu and scientists at Massachusetts General Hospital and ... in Science , Yu and her colleagues report ... blood streams of six patients. Some of these deadly ... to and establish secondary tumors in vital organs such ...
(Date:7/11/2014)... July 11, 2014 Cancer researchers in ... a significant impact on how patients respond to treatment ... mesothelioma. Surviving Mesothelioma has the full story. Click ... Researchers at the University of Ljubljana and the Ljubljana ... for different types of polymorphisms. They found that ...
(Date:7/11/2014)... Re-tearing a repaired knee Anterior Cruciate Ligament (ACL) ... presented today at the American Orthopaedic Society for Sports ... and patient education regarding modifiable risk factors may minimize ... “Our research suggests that a few risk factors such ... may point to the possibility of re-injury,” said lead ...
Breaking Medicine News(10 mins):Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 2Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 3Health News:Psychiatric Hospital Patient and Registered Psychologist Explores Mental Health and Therapy in New Book "You Never Get Out" 2Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:New Study May Identify Risk Factors for ACL Re-injury 2
... general practitioners , who were free of dementia ... years and 3 years later by means of ... alcohol consumption and DSM-IV dementia diagnoses. Associations between ... alcohol (wine, beer, mixed alcohol beverages) and incident ...
... 7, 2011 Elsevier, the leading global publisher ... announced today it has begun offering Arabic bilingual editions ... the Middle East. The first order was recently received ... one of Elsevier,s many meant to help improve the ...
... , The U.S. spends around 2 billion dollars a ... large portion of this used for groundwater monitoring. Yet ... University,s Biodesign Institute, the information gathered is often of ... grant from the U.S. Department of Defense, Halden, assistant ...
... The 2011 Sleep in America poll released today by the National ... hour before bed. It also finds that a significant number of ... searching for ways to cope. , Many Americans report dissatisfaction ... 43% of Americans between the ages of 13 and 64 say ...
... heart disease, involving scientists from the University of ... of heart attacks. Professor Nilesh Samani, British ... Leicester, based at Glenfield Hospital, who co-led the international ... genes identified were not previously known to be involved ...
... Creating a healthy eating action plan and visualizing yourself carrying ... suggest. "Telling people to just change the way they ... study author Barbel Knauper, an associate professor of psychology at ... "But research has shown that if people make a ...
Cached Medicine News:Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 2Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 3Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 4Health News:Monitoring waste in groundwater (without all the waste) 2Health News:Sleepy connected Americans 2Health News:Sleepy connected Americans 3Health News:Sleepy connected Americans 4Health News:Sleepy connected Americans 5Health News:Sleepy connected Americans 6Health News:Leicester leads on heart attack genetic link discovery 2
... Merlin is a superior full-color, auto-focus, desktop ... user in mind, Merlin enables the user ... and white, high contrast positive or high ... magnifier, this optional feature enables the user ...
... general purpose incubators designed to ... and uniformity required for the ... versatile microprocessor controlled incubators feature ... easy-to-read digital display, and built-in ...
... Economy Incubators available in five different models. ... 1.4 cu. Ft. (39 liters), 2.5 cu. ... (129 liters. Equally important, Precision Economy Incubators ... temperature sensitivity, stability, and uniformity. As a ...
Aspheric diagnostic lens. 90D...
Medicine Products: